Our work suggests that disrupting the supportive role that ASCs provide for tumor cells, either by preventing ASC migration to the chemo-residual tumor microenvironment (Fig. 5A) or by inhibiting the signaling associated with ASC release of growth factors such as FGF2 (Fig. 5B), may prevent TNBC recurrence. The gene discussed is FGF2; the disease is neoplasm.